Compare CSTE & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | ASRT |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7M | 76.0M |
| IPO Year | 2012 | 2004 |
| Metric | CSTE | ASRT |
|---|---|---|
| Price | $1.78 | $23.47 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 163.0K | ★ 349.5K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $118,713,000.00 |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $2.83 | $12.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.61 |
| 52 Week High | $2.58 | $23.49 |
| Indicator | CSTE | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 83.64 |
| Support Level | $1.42 | $11.05 |
| Resistance Level | $1.76 | N/A |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 19.74 | 95.46 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa), of which it derives maximum revenue from United States.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.